Onderzoeker
Delphine Verbeke
- Disciplines:Systeembiologie
Affiliaties
- Laboratorium voor Moleculaire Biologie van Leukemie (VIB-KU Leuven) (Afdeling)
Lid
Vanaf1 sep 2016 → 31 okt 2020
Projecten
1 - 2 of 2
- Combinatie van doelgerichte therapie en chemotherapie bij acute lymfatische leukemieVanaf1 okt 2016 → 30 sep 2020Financiering: Privé-financiering van binnenlandse oorsprong - onbepaald
- Combinatietherapieën voor acute lymfoblastische leukemieVanaf1 sep 2016 → 31 okt 2020Financiering: FWO Strategische Onderzoeksbeurs
Publicaties
1 - 8 van 8
- The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia(2020)
Auteurs: Delphine Verbeke, Sofie Demeyer, Jolien De Bie, Anne Uyttebroeck, Nancy Boeckx, Kim De Keersmaecker, Johan Maertens, Heidi Segers, Jan Cools
Pagina's: 5747 - 5758 - Combining targeted therapy and chemotherapy in acute lymphoblastic leukemia(2020)
Auteurs: Delphine Verbeke, Jan Cools, Heidi Segers
- Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia(2019)
Auteurs: Delphine Verbeke, Nancy Boeckx, Kim De Keersmaecker, Johan Maertens, Anne Uyttebroeck, Heidi Segers, Jan Cools
- Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition(2019)
Auteurs: Charles De Bock, Inge Lodewijckx, Delphine Verbeke, David Nittner, Sofie Demeyer, James Dooley, Adrian Liston, Jan Cools, Bart De Strooper
- Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia (vol 32, pg 788, 2018)(2018)
Auteurs: Sandrine Degryse, CE de Bock, S Demeyer, Inge Govaerts, Simon Bornschein, Delphine Verbeke, K Jacobs, S Binos, DA Skerrett-Byrne, HC Murray, et al.
Pagina's: 2731 - 2731 - Malt1 self-cleavage is critical for regulatory Tcell homeostasis and anti-tumor immunity in mice(2018)
Auteurs: Rocco Stirparo, Youlia Lampi, Delphine Verbeke, Jan Cools, Peter Marynen, Charles De Bock, Simon Bornschein
Pagina's: 1728 - 1738 - Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia(2018)
Auteurs: Sandrine Degryse, Charles De Bock, Sofie Demeyer, Inge Govaerts, Simon Bornschein, Delphine Verbeke, Jan Cools
Pagina's: 788 - 800 - HOXA9 cooperates with activated JAK/STAT signaling to drive leukemia development(2018)
Auteurs: Charles De Bock, Sofie Demeyer, Sandrine Degryse, Delphine Verbeke, Marlies Vanden Bempt, Ellen Geerdens, Simon Bornschein, Rik Gijsbers, Jan Cools
Pagina's: 616 - 631